scholarly journals THE ASSOCIATION BETWEEN EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR WITH PRIMARY TUMOR VOLUME OF NASOPHARYNGEAL CARCINOMA

2019 ◽  
Vol 1 (1) ◽  
pp. 36-40
Author(s):  
Audi Wahyu Utomo ◽  
Indah Asmara Gustarini
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Nasopharyngeal Carcinoma ◽  
Primary Tumor ◽  
Tumor Volume ◽  
Growth Factor Receptor ◽  
Primary Tumor Volume ◽  
Positive Expression ◽  
Egfr Expression ◽  
Epidermal Growth

Objective: Tumor development was triggered by the excess population of the Epidermal Growth Factor Receptor (EGFR). Expression of EGFR with primary tumor volume of in patients with NPC. Expression of EGFR has a role in the increasing of metastasis, self-renewal, drug resistance and anti-apoptosis. EGFR expression associated with tumors size, positively nodules and advanced tumor stage in NPC patients. High level of EGFR expression by immunohistochemical examination associated with the development, progression and differentiation cell of tumors. Methods: Using Cross-sectional as study design. Formalin-fixed paraffin-embedded biopsy specimens were obtained. The expression of EGFR was studied with immunohistochemistry using EGFR polyclonal antibody (Bioss, USA). Assessment of the staining was performed by pathologist consultant used histoscore. The Pearson’s correlation test was used to determine the correlation between expression of EGFR and primary tumor volume of nasopharyngeal carcinoma. Statistical significance was defined as p <0.05. Result: Total samples are 19 patients. The result of EGFR expression in NPC patients with a primary tumor volume of 1-50 ml is 5 samples with a weak positive expression and 4 samples with moderate positive expression. NPC with a primary tumor volume of 51-100 ml is 2 samples of negative expression, 1 sample of weak positive expression, 3 samples with moderate positive expression and 2 samples with strong positive expression. NPC with primary tumor volume >100 ml is 1 sample weak positive expression and 1 sample strong positive expression. Statistical analysis using Pearson’s exact test was obtained p=0.047 with a correlation coefficient 0.461. EGFR expression from all of the patients there was 2 samples (10.53%) negatives, 7 samples (36.84%) weak positive, moderate positive was 7 samples (36.84%), and strong positive 3 samples (15.79%).  Conclusion: There was an association between the expression of EGFR with the primary tumor volume of nasopharyngeal carcinoma.

scholarly journals EPIDERMAL GROWTH FACTOR RECEPTOR EXPRESSION IN NON-KERATINIZED NASOPHARYNGEAL CARCINOMA SUBTYPE AT PADANG

2019 ◽  
Vol 1 (02) ◽  
pp. 73-74
Author(s):  
Histawara Subroto ◽  
Sukri Rahman ◽  
Bestari J Budiman ◽  
Aswiyanti Asri ◽  
Hafni Bachtiar
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Nasopharyngeal Carcinoma ◽  
Epidermal Growth Factor ◽  
Clinical Stage ◽  
Growth Factor Receptor ◽  
Receptor Expression ◽  
Cross Sectional ◽  
Egfr Expression ◽  
Epidermal Growth

Introduction: Patients with nasopharyngeal carcinoma have a poor prognosis, there are several factors that cause it to happen, one of the existing therapeutic response has been inadequate. Expression of Epidermal Growth Factor Receptor (EGFR) has been used as a biological marker targeted therapy in nasopharyngeal carcinoma. Histopathologic subtype tumors also determine the prognosis of patients with nasopharyngeal carcinoma. Objective: The aim of the study to determine between the expression of epidermal growth factor receptor between non-keratinized differentiated and undifferentiated subtypes in nasopharyngeal carcinoma and correlation with their clinical stage. Study design, Cross-sectional comparative study. Place and duration study, Department of Otorhinolaryngology, Department of Pathology Anatomy in Dr. M. Djamil Hospital, Padang and Department of Pathology Anatomy in Gajah Mada University, between May 2015 until October 2015 Material and methods: We included 36 samples paraffin blocks of nasopharyngeal carcinoma biopsy, respectively 18 paraffin blocks are non-keratinized differentiated and 18 non-keratinized undifferentiated nasopharyngeal carcinoma subtypes. Each sample examined EGFR expression by immunohistochemical staining methods. Results: There were positive EGFR expression results in all sample as 69.4%. Expression of EGFR positive non-keratinized differentiated subtypes in nasopharyngeal carcinoma as 77.8% and undifferentiated subtype as 61.6%. There are no significant differences of EGFR expression between non keratinized differentiated and undifferentiated subtypes nasopharyngeal carcinoma (P>0.05). There are no significant differences of EGFR expression between new and advanced stage nasopharyngeal carcinoma (P>0.05). Conclusion: There were no significant differences of EGFR expression between non-keratinized differentiated and non-keratinized undifferentiated subtypes in nasopharyngeal carcinoma. Analysis of the study also showed no significant differences of EGFR expression based on the clinical stage nasopharyngeal carcinoma.

scholarly journals Discrepant expression and prognostic role of epidermal growth factor receptor and icotinib radiosensitization for nasopharyngeal carcinoma

2020 ◽  
Author(s):  
Bo Wu ◽  
Hua-cai Xiong ◽  
Yong Wang ◽  
Hong-sheng Lu ◽  
Qi Chen ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Prognostic Factor ◽  
Nasopharyngeal Carcinoma ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Disease Free Survival ◽  
Poor Prognostic Factor ◽  
Egfr Expression ◽  
Epidermal Growth

Abstract Background: Epidermal growth factor receptor (EGFR) expression was observed in many tumors. Icotinib (IH), an EGFR tyrosine kinase inhibitor, could enhance the radiosensitivity, but few studies have focused on nasopharyngeal carcinoma (NPC). Materials and Methods : One hundred fifteen NPC lesions and 30 nasopharyngitis lesions were enrolled for EGFR expression evaluation with immunohistochemical staining. The correlation of EGFR expression and clinical parameters was analyzed. Survival analysis was calculated using univariate and multivariate analysis. A radioresistant NPC cell line, CNE-2R, was established with a gradient irradiation schedule of 60 Gy from CNE-2. Cell viability of CNE-2/2R was detected using microculture tetrazolium assay and colony-forming assay. The IH radiosensitization effect and EGFR expression were also evaluated in CNE-2/2R. Results: High EGFR expression was more frequently detected in NPC lesions (73/115) than chronic nasopharyngitis lesions (5/30, p =0.000). EGFR expression was correlated with tumor stage ( p =0.000) and tumor-node-metastasis (TNM) stage ( p =0.006). EGFR expression was an independent prognostic factor of disease-free survival ( p =0.047) and overall survival ( p =0.016). The optical density value of CNE-2R was higher than CNE-2 on days 1, 2, 4, and 6 after radiation of 4 Gy ( p <0.005). CNE-2 colony numbers clearly decreased compared with CNE-2R ( p <0.05), and IH enhanced the radiosensitizing effect of CNE-2R with an apparently lower survival fraction (1.414 times, p <0.05). Higher EGFR expression was observed in CNE-2R cells and decreased accordingly when exposed to IH. Conclusion: High EGFR expression was more frequently detected as a poor prognostic factor in NPC patients. Higher radioresistance and EGFR expression were observed in CNE-2R, and IH could reduce it. These results provided a new theoretical basis for clinical application of icotinib radiosensitization in NPC radiotherapy.

scholarly journals Epidermal growth factor receptor protein expression in lung cancer and survival analysis

2018 ◽  
Vol 5 (3) ◽  
pp. 550
Author(s):  
Shivalingaswamy Salimath ◽  
Jayaraj B. S. ◽  
Mahesh P. A. ◽  
M. D. Majeed Pasha ◽  
Lokesh K. S. ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Multivariate Analysis ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Performance Status ◽  
Growth Factor Receptor ◽  
Egfr Expression ◽  
Epidermal Growth ◽  
Nsclc Patients

Background: Epidermal Growth Factor Receptor (EGFR) is one of the important molecules involved in lung cancer initiation and progression. Studies on over expression of EGFR and its survival in relation with Non-small cell lung cancer (NSCLC) patients have yielded controversial results. Prevalence of EGFR expression in NSCLC patients and 6-month survival in south Indian population is unknown.Methods: We carried out a prospective study in tertiary hospital. Diagnosed patients with NSCLC were included in the study and were interviewed with questionnaire containing demography and investigations like Chest X-ray, CT thorax, Bronchoscopy were recorded. EGFR expression analysis was done for all patients and were followed up monthly for 6 months and details of survival and treatment were collected. Cox regression analysis was used to assess their survival.Results: 50 patients with NSCLC were included. Forty-four (88%) were men, median age of study group was 65 years. Twenty-seven patients (54%) had Adenocarcinoma, 14 patients (28%) had Squamous cell carcinoma, 7 patients (14%) had poorly differentiated carcinoma and 2 patients (4%) had large cell carcinoma. Thirty-four (68%) samples were positive for EGFR expression. On multivariate analysis we found patients who took chemotherapy and with good performance status (Karnofsky score >65 and Eastern Cooperative Oncology Group >2.5) had better survival at 6 months.Conclusions: Patients with EGFR positivity had better survival with chemotherapy but worse with radiotherapy. Patients who took chemotherapy and had good performance status had better survival on multivariate analysis. We didn’t find any correlation between EGFR positivity and poor survival.

scholarly journals Inhibition of epidermal growth factor receptor (EGFR) expression by human cytomegalovirus correlates with an increase in the expression and binding of Wilms' Tumour 1 protein to the EGFR promoter

2009 ◽  
Vol 90 (7) ◽  
pp. 1569-1574 ◽  
Author(s):  
Insiya Jafferji ◽  
Mark Bain ◽  
Christine King ◽  
John H. Sinclair
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Human Cytomegalovirus ◽  
Growth Factor Receptor ◽  
Cell Surface Receptor ◽  
Wilms Tumour ◽  
Promote Cell Proliferation ◽  
Egfr Expression ◽  
Epidermal Growth

Infection with human cytomegalovirus (HCMV) modulates the expression of a number of cellular receptors and is known to inhibit expression of the epidermal growth factor receptor (EGFR), a cell surface receptor that can promote cell proliferation through a cascade of intracellular signalling events. We have examined the mechanisms by which HCMV mediates downregulation of EGFR expression and show that virus infection results in the profound upregulation of Wilms' Tumour 1 (WT1) protein, a transcription factor associated with the negative regulation of a number of growth factors and growth factor receptors, including EGFR. Moreover, chromatin immunoprecipitation experiments also show that HCMV infection results in increased binding of WT1 to the EGFR promoter. Finally, we show that depleting the cell of WT1 using small interfering RNA abrogates virus-mediated downregulation of EGFR. Taken together, our observations suggest that HCMV-mediated repression of EGFR expression results from a virus-mediated increase in cellular WT1, a known pleiotropic regulator of mitogenesis, apoptosis and differentiation.

Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer

2006 ◽  
Vol 24 (19) ◽  
pp. 3069-3074 ◽  
Author(s):  
Philip A. Philip ◽  
Michelle R. Mahoney ◽  
Cristine Allmer ◽  
James Thomas ◽  
Henry C. Pitot ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Skin Rash ◽  
Group Performance ◽  
Growth Factor Receptor ◽  
Locoregional Therapy ◽  
Biliary Cancer ◽  
Egfr Expression ◽  
Epidermal Growth

Purpose Epidermal growth factor receptor/human epidermal growth factor receptor 1 and ligand expression is common in biliary cancers (BILI) and may be associated with worse outcome. The primary objective of this study was to determine the proportion of patients with advanced BILI who were progression-free at 6 months. Methods Patients with either unresectable or metastatic disease were studied. Only one prior systemic or locoregional therapy was allowed. Erlotinib was administered continuously at a dose of 150 mg per day orally. Results Forty-two patients with BILI were enrolled. The median age was 67 years (range, 33 to 82 years). Fifty-two percent of patients had Eastern Cooperative Oncology Group performance status of 1. Fifty-seven percent of patients had received prior chemotherapy for advanced BILI. HER1/EGFR expression by immunohistochemistry in tumor cells was detected in 29 (81%) of the 36 assessable patients. Seven of the patients (17%; 95% CI, 7% to 31%) were progression free at 6 months. Three patients had partial response by Response Evaluation Criteria in Solid Tumors Group classification of duration 4, 4, and 14 months, respectively. All responding patients had mild (grade 1/2) skin rash and two patients had positive tumoral HER1/EGFR expression. Three patients (7%) had toxicity-related dose reductions of erlotinib due to grade 2/3 skin rash. Conclusion Results suggest a therapeutic benefit for EGFR blockade with erlotinib in patients with biliary cancer. Additional studies with erlotinib as a single agent and in combination with other targeted agents are warranted in this disease.

Sign in / Sign up

Export Citation Format

Share Document